Key Highlights
- Revenue of USD 8.58 million missed the USD 13.75 million estimate, down 24%; the loss was USD 0.16 per share.
- UltraMIST system Revenue fell about 73% to USD 1.2 million, while applicator unit Volume rose 15% year over year.
- Gross Margin was 77.3% against 77.6%, and net loss was USD 1.4 million against Net Income of USD 9.7 million.
- Cash and cash equivalents were USD 6.57 million against USD 11.96 million at the end of the prior year.
SANUWAVE Health, Inc. (NASDAQ:SNWV), a wound care and regenerative medicine device company, reported third quarter 2026 revenue of USD 8.58 million, below the USD 13.75 million estimate and down 24% from USD 11.3 million. The loss of USD 0.16 per share compared with estimated Earnings of USD 0.01. Net loss was USD 1.4 million against net income of USD 9.7 million a year earlier.
For the nine months, revenue was USD 27.9 million, down 9% from USD 30.7 million, and net loss was USD 3.5 million against net income of USD 4.1 million.
System and Applicator Trends
Management said UltraMIST system revenue declined about 73% to USD 1.2 million from USD 4.4 million on a 74% decline in unit volume, which it attributed to weaker Capital sales amid financial pressure on customers. It said systems sold dropped from 82 in the second quarter to 40 in the third, as used systems from former customers closing their doors continue to compete with new sales.
Applicator revenue grew 2% year over year with applicator unit volume up 15%, which management said reflects continued strong utilization across the active installed base. Applicator revenue declined about 4% from the second quarter, which remains the highest quarterly total ever.
Margins, Costs and Cash
Gross margin was 77.3% against 77.6%, a decrease of about 32 basis points. Management said the swing reflects roughly USD 2.1 million of lower gross margin, partly offset by roughly USD 0.1 million of lower operating expenses. Non-cash stock-based compensation within operating expenses was about USD 1.5 million against USD 1.4 million.
Cash and cash equivalents were USD 6.57 million at September 30, 2026 against USD 11.96 million at the prior year end, with Accounts Receivable of USD 4.97 million and inventory of USD 6.72 million.
Regulatory Commentary and Items to Follow
Management said the quarter was defined by the CMS proposed rule, including the choice not to increase skin substitute reimbursement prices for 2027. It said CMS chose to mostly implement the rule as drafted with minor changes, such as raising the kit price component to USD 125 from USD 100 and including saline expense, and estimated the 2027 physician fee schedule payment for code 97610 at USD 314.54. It also said some groups asked CMS to delay finalization pending a review process.
The filing refers to its legal proceedings note, which is reported there and flagged for human legal review. Management said the decrease in nine-month system revenue was primarily driven by a 40% decline in unit volume reflecting weaker capital sales, while applicator revenue rose on a 21% increase in unit volume. The items to follow are system unit volume, applicator utilization, reimbursement rules, gross margin and cash.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...